Reuters logo
BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106
September 27, 2017 / 7:28 AM / 3 months ago

BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106

Sept 27 (Reuters) - Galapagos Nv

* Co, Morphosys report first promising signs of clinical activity in phase 1 study with IL-17C antibody MOR106 in Atopic Dermatitis patients

* Says generally well-tolerated with no clinically relevant safety signals in phase 1 study

* Says clinical phase 1 study results support progression to phase 2 study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below